About Us
The Buchholz Lab
Systems biology and genome engineering are at the forefront of transforming our healthcare system. The Department of Medical Systems Biology at the University Cancer Center of TU Dresden integrates functional genomics, high-throughput biology and genome editing to transform precision medicine. Join us in shaping the future of healthcare science!
Prof. Dr. Frank Buchholz
Frank is passionate about the development and application of functional genomics and genome engineering in biomedical science. He was one of the first scientists to perform genome-scale RNAi screens in human cells, and has pioneered genome surgery as a disruptive new biotechnology. Frank has also been a strong leader in industrial innovation and co-founded several biotechnology companies.
Prof. Dr. Frank Buchholz
Frank is passionate about the development and application of functional genomics and genome engineering in biomedical science. He was one of the first scientists to perform genome-scale RNAi screens in human cells, and has pioneered genome surgery as a disruptive new biotechnology. Frank has also been a strong leader in industrial innovation and co-founded several biotechnology companies.
Research
Find out more about our research
Publications
Follow the work of our researchers
Members
Your contact to our research group members
News
Get to know the news of our research group
News
Haidy Saleh Hassan and Frank Buchholz contribute to EMBO CRISPR-Cas Workshop
5. November 2025
The EMBO Workshop CRISPR-Cas: From Biology to Therapeutic Applications showcased groundbreaking research in gene editing. Our lab was represented by Haidy Saleh Hassan and Frank Buchholz. Haidy…
Buchholz Lab awarded federal grant to translate CRISPR technology towards innovative cancer research
14. October 2025
The research group of Prof. Dr. Frank Buchholz is thrilled to announce the successful acquisition of a grant for the project "CanCorrect," aimed at revolutionizing cancer research, diagnostics, and…
Buchholz Lab Publication Alert
31. July 2025
Our new study “A base editing platform for the correction of cancer driver mutations unmasks conserved p53 transcription programs” reveals how correcting TP53 mutations uncovers universal cancer…











